Royalty Retained Earnings Total Equity from 2010 to 2025
| RPRX Stock | USD 39.73 0.14 0.35% |
Retained Earnings Total Equity | First Reported 2010-12-31 | Previous Quarter 2.3 B | Current Value 2.3 B | Quarterly Volatility 133 M |
Check Royalty Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Royalty Pharma's main balance sheet or income statement drivers, such as Interest Expense of 236.8 M, Total Revenue of 1.2 B or Research Development of 1.9 M, as well as many indicators such as Price To Sales Ratio of 4.77, Dividend Yield of 0.0363 or PTB Ratio of 1.56. Royalty financial statements analysis is a perfect complement when working with Royalty Pharma Valuation or Volatility modules.
Royalty | Retained Earnings Total Equity | Build AI portfolio with Royalty Stock |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Royalty Stock Analysis
When running Royalty Pharma's price analysis, check to measure Royalty Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Royalty Pharma is operating at the current time. Most of Royalty Pharma's value examination focuses on studying past and present price action to predict the probability of Royalty Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Royalty Pharma's price. Additionally, you may evaluate how the addition of Royalty Pharma to your portfolios can decrease your overall portfolio volatility.